TY - JOUR
T1 - Nonmyeloablative alternative donor transplants
AU - Luznik, Leo
AU - O'Donnell, Paul V.
AU - Fuchs, Ephraim J.
PY - 2003/3
Y1 - 2003/3
N2 - The advent of nonmyeloablative preparative regimens and the expected lower regimen-related toxicities associated with them hold significant promise for extension of the use of allogeneic hematopoietic stem cell transplantation. Nonmyeloablative hematopoietic stem cell transplantation using human leukocyte antigen matched sibling donor, which carries a relatively low risk of transplant-related complications and can result in impressive antitumor responses, may benefit older patients and patients with preexisting organ impairment. However, more than 65% of patients in need of this procedure lack a human leukocyte antigen matched sibling donor. Therefore, attention has focused on alternative donors such as genotypically matched unrelated donors and partially mismatched related donors. Early clinical results suggest that the use of alternative donors is feasible, therefore potentially allowing full extension of the benefits of allografting to the group of patients in highest need.
AB - The advent of nonmyeloablative preparative regimens and the expected lower regimen-related toxicities associated with them hold significant promise for extension of the use of allogeneic hematopoietic stem cell transplantation. Nonmyeloablative hematopoietic stem cell transplantation using human leukocyte antigen matched sibling donor, which carries a relatively low risk of transplant-related complications and can result in impressive antitumor responses, may benefit older patients and patients with preexisting organ impairment. However, more than 65% of patients in need of this procedure lack a human leukocyte antigen matched sibling donor. Therefore, attention has focused on alternative donors such as genotypically matched unrelated donors and partially mismatched related donors. Early clinical results suggest that the use of alternative donors is feasible, therefore potentially allowing full extension of the benefits of allografting to the group of patients in highest need.
UR - http://www.scopus.com/inward/record.url?scp=0242500985&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0242500985&partnerID=8YFLogxK
U2 - 10.1097/00001622-200303000-00001
DO - 10.1097/00001622-200303000-00001
M3 - Review article
C2 - 12601275
AN - SCOPUS:0242500985
SN - 1040-8746
VL - 15
SP - 121
EP - 126
JO - Current opinion in oncology
JF - Current opinion in oncology
IS - 2
ER -